A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

  • 7/14/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Credit Suisse Group to a “hold” rating. They now have a $485.00 price target on the stock.
  • 7/10/2017 – Regeneron Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $450.00 price target on the stock, up previously from $405.00.
  • 7/6/2017 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/4/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and Regeneron is evaluating the drug for additional indications like asthma. The approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU will further diversify the company’s portfolio. On the other hand, although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is expected to have blockbuster potential. Shares of the company have also outperformed the industry in the year so far.”
  • 6/30/2017 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $540.00 price target on the stock, up previously from $480.00.
  • 6/28/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $573.00 price target on the stock, up previously from $493.00.
  • 6/26/2017 – Regeneron Pharmaceuticals was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $480.00 price target on the stock, up previously from $410.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 6/24/2017 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/22/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $547.00 price target on the stock, up previously from $475.00.
  • 6/22/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $573.00 price target on the stock.
  • 6/21/2017 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $421.00 price target on the stock.
  • 6/20/2017 – Regeneron Pharmaceuticals was given a new $484.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 6/20/2017 – Regeneron Pharmaceuticals had its price target raised by analysts at Piper Jaffray Companies from $446.00 to $557.00. They now have an “overweight” rating on the stock.
  • 6/14/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 6/13/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $493.00 price target on the stock.
  • 5/25/2017 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 498.11 on Tuesday. The firm has a market cap of $52.59 billion, a price-to-earnings ratio of 60.30 and a beta of 1.67. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The stock’s 50 day moving average price is $474.83 and its 200-day moving average price is $400.97.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, beating the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same quarter in the prior year, the company earned $2.57 EPS. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post $12.73 EPS for the current year.

In related news, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the director now owns 3,000 shares in the company, valued at approximately $1,350,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now owns 414,156 shares in the company, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.